- Home
- / Shanghai Shenlian Biomedical
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Shanghai Shenlian Biomedical financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
¥5
2024-10-29
Market Capitalization
¥2 B
2024-10-29
Revenue
¥297.6 M
FY, 2024
CreditSafe Score
?
Score changed on Jun 10, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| CNY | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 272.1M | 250.9M | 334.4M | 354.2M | 324.4M | 295.7M | 297.6M |
| Cost of goods sold | 54.6M | 45.0M | 55.1M | 87.0M | 81.4M | 87.9M | 120.6M |
| Gross profit | 217.6M | 206.1M | 279.7M | 267.9M | 243.8M | 209.1M | 178.4M |
| Gross profit margin, % | 82.1% | 83.6% | 75.6% | 75.1% | 70.7% | 60.0% | |
| Operating expense total | 114.3M | 115.9M | 134.4M | 112.3M | 110.8M | 116.1M | 165.4M |
| Depreciation and amortization | 11.9M | 15.0M | 20.8M | 43.6M | 56.9M | 63.2M | 68.1M |
| EBITDA | 103.3M | 90.2M | 145.2M | 155.6M | 133.0M | 93.1M | 13.1M |
| EBITDA margin, % | 36.0% | 43.4% | 43.9% | 41.0% | 31.5% | 4.4% | |
| EBIT | 95.9M | 80.4M | 133.2M | 114.1M | 70.6M | 31.9M | (59.3M) |
| EBIT margin, % | 32.0% | 39.8% | 32.2% | 21.8% | 10.8% | -19.9% | |
| Interest income | 3.4M | 5.3M | 2.2M | 1.6M | 1.0M | 985.0K | 811.0K |
| Interest expense | 7.0K | 17.0K | |||||
| Pre tax profit | 101.3M | 90.8M | 150.0M | 126.0M | 74.6M | 36.3M | (56.8M) |
| Income tax expense | 13.7M | 12.9M | 20.6M | 21.5M | 13.6M | 6.4M | (8.0M) |
| Net Income | 87.6M | 78.0M | 129.4M | 104.5M | 61.0M | 29.9M | (48.7M) |